Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASAP II: Talc Instillation for Malignant Pleural Effusion
NCT04792970Phase 4Terminated
- Sponsor
- Duke University
- Start
- Mar 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of talc in malignant pleural effusion (MPE) (2 arms), sponsored by Duke University. Primary endpoint: Percentage of Participants Undergoing Accelerated Pleurodesis at 90 days. Started Mar 2021; status: terminated.
02
Drugs
talc
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT04792970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792970.